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Abstract
The mechanisms resulting in progressive immune dysfunction during the chronic phase of HIV infection are not fully
understood. We have previously shown that arginase, an enzyme with potent immunosuppressive properties, is increased
in HIV seropositive (HIV+) patients with low CD4+ T cell counts. Here we show that the cells expressing arginase in
peripheral blood mononuclear cells of HIV+ patients are low-density granulocytes (LDGs) and that whereas these cells have
a similar morphology to normal-density granulocyte, they are phenotypically different. Importantly, our results reveal that
increased frequencies of LDGs correlate with disease severity in HIV+ patients.
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Introduction
Since the initial report of AIDS in 1981, approximately 60
million people have become infected with HIV of which more
than 30 million have died. Although depletion of CD4+ T cells
explains much of the immune suppression in HIV infected
individuals, the precise reasons for the onset of immunopathology
during HIV infection are not yet fully understood [1,2,3,4].
Arginase, an enzyme of the urea cycle, can also be expressed in
cells of the immune system and has been shown to exert potent
immunoregulatory functions: a reduction in the bioavailability of
L-arginine by arginase results in impaired T cell responses,
characterized by down-regulation of T cell proliferation, reduced
expression of CD3f and cytokine production [5,6,7,8]. To date,
two mechanisms by which arginase depletes L-arginine have been
described:
1) Transport of extracellular L-arginine into the cells by cationic
amino acid transporter (CAT)2B to make it accessible for
catabolization by arginase results in depletion of L-arginine in
the microenvironment [9,10];
2) Arginase can be released by neutrophils into the extracellular
milieu, where it binds L-arginine and thereby reduces the
level of free L-arginine available to T cells [11].
We have previously shown that arginase activity is higher in
peripheral blood mononuclear cells (PBMCs) isolated from HIV-1
infected individuals with low CD4+ T cell counts and that this
coincided with lower levels of L-arginine [12]. In the present
study, we characterized the phenotype of arginase-expressing cells
in HIV+ patients and tested the hypothesis that their frequency
correlated with markers of disease severity.
Materials and Methods
Subjects and Samples
Thirtytwo HIV seropositive (HIV+) treatment-naı¨ve individuals
(mean age 42.1612.2 years) were recruited from St Mary’s
Hospital and 11 healthy volunteers (mean age 3564.7 years) were
recruited as control subjects. The study was approved by the
National Research Ethics Service (05/Q0410/93) and all individ-
uals gave written, informed consent before participation.
Twenty ml of peripheral blood was collected in EDTA tubes
and PBMCs were isolated by density gradient centrifugation on
HistopaqueH-1077 (Sigma). Neutrophils were isolated from the
erythrocyte fraction by dextran sulphate sedimentation [13].
Flow cytometry. The following antibodies were used:
CD14FITC, CD15PE (BD Pharmingen), Arginase1Alexa FluorH 647
(Hycult Biotechnology), CD11bPerCP-eFluro710, CD16eFluro450,
CD33PE-Cy7 (eBioscience), CD13APC-Cy7 (Biolegend), CD66bFITC
and CD63FITC (Beckman Coulter) (Tables 1 and 2). Analysis was
performed on an FACS Canto II (BD Bioscience) and results were
analyzed using FlowJo v8.7 (Tree Star, Ashland, OR).
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Isolation of CD15+ cells. CD3+ and CD14+ cells were
removed by positive selection, CD15+ cells were incubated with
anti-CD15PE and selected using EasySep PE Positive Selection Kit
(EasySep, Stem Cell Technologies, France). Purity of CD15+ cells
was checked by flow cytometry (.95%). The remaining cells were
transferred onto a microscope slide (Thermo Scientific, United
Kingdom) using a cytospin centrifuge and stained with hematox-
ylin and eosin (H&E) (Reagena, Gamidor, United Kingdom).
Statistical Analyses
Data were evaluated for statistical differences using a Wilcoxon
signed rank test, a two-tailed Mann-Whitney test and a Spear-
man’s rank test when appropriate (GraphPad Prism 5); differences
were considered statistically significant at p,0.05. Unless other-
wise specified, results are expressed as median6SEM.
Results
Phenotypic Characterization of Different Populations of
Granulocytes
We have previously shown that arginase activity is significantly
higher in PBMCs of HIV+ individuals with low CD4+ T cell
counts. Furthermore, we showed that the cells expressing arginase
in the PBMC fraction are granulocytes [12]. Typically granulo-
cytes sediment with erythrocytes following density gradient
centrifugation. Based on this difference in density we refer to
granulocytes that co-purify in the PBMC fraction as low-density
granulocytes (LDGs) and granulocytes which sediment with
erythrocytes as normal-densitiy granulocytes (NDGs). To deter-
mine whether these two populations of granulocytes can be
distinguished morphologically and phenotypically, we purified
LDGs and NDGs and stained both populations with H&E. As
shown in Figure 1, despite a difference in density, these two
populations are morphologically similar: they are mature,
segmented neutrophils. To answer whether they differ phenotyp-
ically, we assessed the expression levels of a panel of phenotypic
markers of neutrophils. The mean fluorescence intensities (MFI) of
CD11b, CD15, CD33 and CD66b were significantly greater
(Figures 2 A–D) on LDGs than on NDGs. CD16 MFI was
significantly reduced on LDGs (Figure 2 E). No significant
difference was observed in the MFI of CD13 (Figure 2 F).
To establish whether this phenotype differs from that of healthy
individuals, we measured the expression levels of the same panel of
cell surface markers on LDGs and NDGs from healthy individuals.
As shown in table 3, there was also an increase in the MFI of
CD15, CD33, CD63 and CD66b, and a decrease in the MFI of
CD16 and arginase 1. There were no significant differences in the
MFI of CD11b. However, there was a significant decrease in
CD13 MFI on LDGs as compared to NDGs (Table 3).
The blood from the controls and HIV+ patient with high or low
CD4+ T cell counts was processed immediately and in the exact
same way, therefore excluding that any differences observed were
due to the handling procedure.
These results show that NDGs and LDGs are morphologically
mature neutrophils, but that they differ in the expression level of
markers of polymorphonuclear cells.
Table 1. Phenotype Panel.
Antigen Fluorophore Clone Isotype Produced by Product code Volume used (mL) Quantity (mg)
CD15 PE H198 mouse IgM BD Pharmingen 555402 20 NP
CD11b PerCP-eFluor710 ICRF44 mouse IgG1 eBioscience 46–0118 3 0.075
CD13 APC-Cy7 WM15 mouse IgG1 Biolegend 301710 7 NP
CD16 eFluor 450 eBioCB16 mouse IgG1 eBioscience 48–0168 3 0.15
CD33 PE-Cy7 WM-53 mouse IgG1 eBioscience 25–0338 3 0.15
CD66b FITC 80H3 mouse IgG1 Beckman Coulter IM05310 3 NP
LDGs and NDGs were isolated as described in materials and methods and the expression levels of phenotypic markers were determined by flow cytometry.
NP = Not provided by manufacturer.
doi:10.1371/journal.pone.0048939.t001
Table 2. ARGINASE 1 Panel.
Antigen Fluorophore Clone Isotype Produced by Product code Volume used (mL) Quantity (mg)
CD15 PE H198 mouse IgM BD Pharmingen 555402 20 NP
CD13 APC-Cy7 WM15 mouse IgG1 Biolegend 301710 7 NP
CD16 eFluor 450 eBioCB16 mouse IgG1 eBioscience 48–0168 3 0.15
CD63 FITC CLBGran/12 mouse IgG1 Beckman Coulter IM1165U 14 NP
Arginase 1 Alexa FluorH 647 6G3 mouse IgG1 Hycult biotech. HM2162 2.75 0.275
LDGs and NDGs were isolated as described in materials and methods and the expression levels of phenotypic markers were determined by flow cytometry.
NP = Not provided by manufacturer.
doi:10.1371/journal.pone.0048939.t002
LDGs in HIV Seropositive Individuals
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LDGs Express Higher Levels of CD63 and Lower Levels of
Arginase
In neutrophils, arginase is localized in azurophilic granules [13],
which express CD63; following activation, neutrophils degranulate
and the release of arginase-containing azurophilic granules results
in the incorporation of CD63 into the cell surface membrane of
neutrophils [14,15,16,17]. The arginase released by activated
neutrophils has been shown to induce a profound suppression of T
cell proliferation and cytokine synthesis [18]. To test whether
LDGs have released their azurophilic granules, we measured the
MFI of CD63 on LDGs and the MFI of arginase 1 in LDGs. As
shown in Figures 2 G–H, CD63 MFI was significantly higher
(p,0.0001) and arginase MFI was significantly lower (p=0.0004)
in LDGs as compared to NDGs. These results suggest that LDGs
have degranulated and released their arginase.
The Frequency of LDGs Correlates with Markers of
Disease Severity
Markers of disease severity in HIV-1 infection include CD4+ T
cell count and viral load. Consequently we assessed whether the
frequency of LDGs in healthy controls and HIV patients
correlated with markers of disease severity. First, we compared
the frequency of LDGs in healthy controls and HIV patients. The
frequency of LDG was significantly lower in healthy controls as
compared to HIV+ patients with CD4+ T cell counts .350 cells/
ml (0.2460.3 vs 0.6060.52, p=0.0160) and HIV+ patients with
CD4+ T cell counts ,350 cells/ml (0.2460.3 vs 3.3362.51,
p,0.0001) (data not illustrated). Next we determined whether the
frequencies of LDGs varied between individuals with low or high
CD4+ T cell counts. As shown in Figure 3A, the percentage of
LDGs in the PBMCs of HIV+ individuals with CD4+ T cell counts
,350 cells/ml was significantly higher (3.3362.51 vs 0.6060.52,
p=0.0001). Similar results were obtained with the absolute counts
of LDGs per ml of blood (6.1766.786104 vs 1.9461.416104,
p=0.0037). To assess the potential clinical significance of this
difference, we tested for a correlation between the percentages of
LDGs in the PBMCs against absolute CD4+ T cell count and
HIV-1 viral load. Results in Figure 3B show a strong inverse
correlation between CD4+ T cell counts and percentage of LDGs
(r =20.6908, p,0.0001). There was also a significant correlation
between HIV-1 viral load and percentage of LDGs (Figure 3C,
r = 0.4661, p=0.0108). These results show that in HIV+ patients,
the frequency of LDGs present in PBMCs correlated with markers
of disease severity.
Discussion
Arginase-induced L-arginine catabolism is a well-established
mechanism of immune suppression [5,6,7,8]. We have recently
shown that arginase activity is abnormally high in PBMCs of
untreated HIV+ individuals with low CD4+ T cell counts and that
this coincides with lower levels of L-arginine [12]. Here we
consolidate and extend our previous results and show that the
frequency of arginase-expressing cells is closely associated with the
two most widely accepted markers of disease severity: CD4+ T cell
counts and plasma HIV-1 viral loads.
Following density gradient centrifugation, LDGs co-purify in
the PBMC fraction, whereas NDGs sediment with erythrocytes.
This difference could result from i) different degrees of maturation
and ii) different activation and degranulation states:
i) During neutrophil maturation there is a change in expression
of surface antigens [19]. In untreated HIV+ individuals,
LDGs display high expression levels of CD33, a marker of
immature neutrophils, and lower levels of CD16, a marker
found on mature neutrophils, suggesting that these cells are
immature [19]. A study by Brandau et al. identified immature
granulocytes from individuals with cancer that co-purify in the
PBMC fraction [20]. However, our results show that LDGs
are morphologically similar to NDGs, as they are segmented
neutrophils. We cannot exclude the possibility that the
population of LDGs isolated from HIV+ individuals repre-
sents a heterogeneous population of neutrophils that does not
exclusively comprise mature activated cells; indeed, Rodri-
guez et al showed that in renal cell carcinoma, ,10% of the
myeloid derived suppressor cells (MDSCs) were immature
granulocytes and that ,90% were mature segmented
granulocytes [21].
Figure 1. Morphology of LDGs and NDGs. LDGs and NDGs were
isolated as described in materials and methods and their morphology
was compared after H&E staining. Data show the results of one
representative experiment out of five independent experiments.
doi:10.1371/journal.pone.0048939.g001
LDGs in HIV Seropositive Individuals
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Figure 2. Phenotypic analysis of LDGs and NDGs. LDGs and NDGswere isolated as described in materials andmethods (n=22) and the expression
levels of CD11b (A), CD15 (B), CD33 (C), CD66b (D), CD16 (E), CD13 (F), CD63 (G) and arginase 1 (H) were determined by flow cytometry. Isotype controls:
,1%. Statistical significance was determined by a two-tailed Mann-Whitney test. Box= interquartile range and median; whiskers = range.
doi:10.1371/journal.pone.0048939.g002
LDGs in HIV Seropositive Individuals
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ii) The degree of activation of neutrophils and degranulation
depends on the strength of the activating signal: the order of
granule release follows a strict hierarchy requiring increasing
activation: 1) secretory granules; 2) gelatinous (tertiary)
granules; 3) specific (secondary) granules and 4) azurophilic
(primary) granules. From the panel of markers used in the
present study, the following markers were significantly
increased on LDGs: CD11b, present in the membrane of
secretory vesicles, gelatinase granules and specific granules;
CD63, found in the membrane of azurophilic granules; and
CD66b, detected in the membrane of specific granules.
Further, the intensity of arginase, which is present in
azurophilic granules [13], was lower in LDGs as compared
to NDGs. Our results suggest that LDGs are activated
neutrophils that have degranulated because they have
increased cell surface expression of CD66b, CD63 and
CD11b and decreased intracellular arginase 1 expression.
The presence of CD15+ granulocytes in the PBMC fraction has
been demonstrated in a number of different conditions including
cancer, pregnancy, trauma and SLE, each of which is frequently
accompanied by a degree of immune suppression. We have shown
that arginase-induced L-arginine depletion and the subsequent T
cell inhibition is a mechanism of immune suppression that is
restricted to the site of pathology [22]. Therefore, it is possible that
the increased frequencies of LDGs we observed in the peripheral
blood of HIV+ individuals are only a weak reflection of the events
occurring at the principal sites of HIV infection, i.e. in the solid
lymphoid tissue. Indeed, a recent study showed in a model of
prostate-specific inflammation, that MDSCs isolated from the site
of inflammation were more immunosuppressive than those
isolated from the periphery [23].
The impact of arginase-induced L-arginine depletion on T cell
effector functions has been well established [5,6,7,8]. In HIV+
individuals with low CD4+ T cell counts, we and others have
already reported a pronounced downregulation of CD3f, which is
one of the hallmarks of T cell suppression induced by L-arginine
depletion [12]. We propose that the following mechanism
contributes to poor T cell function in these individuals: LDGs
release arginase, which reduces the concentration of free L-
arginine in the microenvironment [12], thereby preventing
efficient T cell responses. Indeed, we have previously shown that
PMN release their arginase and that this inhibits T cell
proliferation in an arginase-dependent manner [18].
More work is needed to understand the causes of the observed
neutrophil activation and the subsequent release of arginase, as it
is not yet not possible to answer whether it is the virus or the
immune system or a combination of both that accounts for the
increased frequency of activated low-density granulocytes in HIV+
patients. A better understanding of the complex mechanisms
leading to progressively impaired immune functions might prove
helpful in improving the existing treatment not only for HIV+
individuals, but also for other chronic infectious diseases such as
tuberculosis and leishmaniasis, in which a degree of immune
suppression may be caused by abnormal arginase activity.
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